[Ototoxic side effects in patients with ovarian cancer treated with cisplatin].
Cisplatinum (DDP) is a cell cycle-independent drug used to prolong the survival time in ovarian cancer patients operated palliatively. After six therapeutic cycles of 100 mg of cisplatinum (Platidiam, Lachema, Brno) per square meter of body surface each changes in the sensation of hearing like tinnitus without any limitation of the faculty of hearing felt individually have been reported in four out of twelve ovary cancer patients. A high frequency loss of more than 4,000 Hz could be detected by threshold audiometry in three out of these twelve patients.
Behling
H
H
Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Medizinischen Akademie Erfurt.
Spieske
C
C
Krafft
W
W
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014012:Tinnitus / Q000139:chemically induced
D002945:Cisplatin
Ototoxische Nebenwirkungen bei Ovarialkarzinompatienten, die mit Cisplatin behandelt wurden.